期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
VmP方案和全脑放射序贯治疗小细胞肺癌脑转移 被引量:6
1
作者 乐翔 臧秦川 《癌症》 SCIE CAS CSCD 北大核心 2004年第12期1671-1676,共6页
背景与目的:单纯化疗或全脑放射治疗(wholebrainradiotherapy,WBRT)姑息性治疗小细胞肺癌(smallcelllungcancer,SCLC)脑转移,生存期均较短,本研究前瞻性观察比较VmP化疗方案与WBRT的不同序贯方法治疗SCLC脑转移患者的疗效、不良反应和... 背景与目的:单纯化疗或全脑放射治疗(wholebrainradiotherapy,WBRT)姑息性治疗小细胞肺癌(smallcelllungcancer,SCLC)脑转移,生存期均较短,本研究前瞻性观察比较VmP化疗方案与WBRT的不同序贯方法治疗SCLC脑转移患者的疗效、不良反应和生存期。方法:38例SCLC并脑转移初治患者根据使用床位非随机地分为A、B两组,经四格表精确概率法检验两组无显著差异(P>0.05)。A组(VmP-WBRT)采用先化疗2周期后放疗的治疗方法,B组(WBRT-VmP)采用先放疗后化疗2周期的治疗方法。化疗方案VmP:鬼臼噻吩甙(Teniposide,Vm-26)60mg/m2d1~5,顺铂(cisplatin,DDP)25mg/m2d1~3,4周为一治疗周期;WBRT方案:多灶性脑转移患者2周内放疗3Gy×10次;单灶脑转移患者在WBRT后1周内缩野放疗3Gy×5次。序贯治疗完成后继续化疗2~4周期。结果:两组病人治疗后80%以上的患者神经症状改善,两组脑转移癌、肺原发癌有效率和RECIST总客观有效率分别为68.2%和75.0%(P=0.647),77.3%和75.0%(P=0.871),63.6%和56.3%(P=0.646);肿瘤进展时间(timetoprogressions,TTP)分别为6.0个月(95%CI4.4~7.6)和5.0个月(95%CI3.6~6.4)(P=0.383);中位生存期(mediansurvivaltime,MST)分别为12.0个月(95%CI7.9~16.1)和9.0个月(95%CI5.6~12.4)(P=0.049);1年和2年生存率分? 展开更多
关键词 脑转移癌/放射治疗 转移癌/药物疗法 小细胞肺癌/药物疗法
下载PDF
Efficacy and nursing of stereotactic radiotherapy in lung cancer patients with brain metastases
2
作者 Xiaoxia Zhang Wenrong Yin Yueqin Liu 《The Chinese-German Journal of Clinical Oncology》 CAS 2008年第4期210-212,共3页
Objective: To observe the efficacy of stereotactic radiotherapy (SRT) in lung cancer patients with brain metas-tases and explore the nursing for those patients. Methods: From June 2002 to December 2006, 43 patients of... Objective: To observe the efficacy of stereotactic radiotherapy (SRT) in lung cancer patients with brain metas-tases and explore the nursing for those patients. Methods: From June 2002 to December 2006, 43 patients of lung cancer with brain metastases were treated with SRT, 8 of them were treated with the association of whole-brain radiotherapy (WBRT) and 6 of them were treated with combination of chemotherapy. During the period of SRT, the patients were applied with active psychological nursing and diet nursing. We also tried to prevent patients from epicranium injury, and meanwhile, patients were asked to took active convalesce exercise. Results: All patients finished SRT without serious reaction and complication. Local control rate was 81.4%, nervous system symptoms relief rate was 76.7% and KPS score was raised significantly. Survival time ranged from 2 to 34 months, median survival time was 8.5 months, and 6-month, 1-and 2-year survival rates were 58.9%, 26.2%, and 6.0% respectively. Conclusion: SRT was one of the effective palliation treatments for the lung cancer patients with brain metastases, and with the assistance of effective nursing, which would prolong their survival time and improved quality of life. 展开更多
关键词 lung cancer with brain metastases stereotactic radiotherapy (SRT) NURSING EFFICACY
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部